Related Experiment Video
Updated: Mar 28, 2026
10:38
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020
8.0K
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer
Omar M Rashid1, Jose M Pimiento1, Andrew W Gamenthaler1
1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Annals of Surgical Oncology
|December 15, 2015
Summary
This study evaluated a neoadjuvant chemotherapy and radiotherapy regimen for borderline resectable pancreatic cancer. The pathway led to high completion rates and improved survival outcomes after surgery.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Lack of prospective data for a standardized multimodality approach to borderline resectable pancreatic adenocarcinoma leads to varied institutional treatment protocols.
- This study assesses the efficacy of a specific institutional clinical pathway involving neoadjuvant chemotherapy (gemcitabine, docetaxel, capecitabine) and stereotactic radiotherapy, followed by surgical resection.
Purpose of the Study:
- To investigate the outcomes of a defined clinical pathway for borderline resectable pancreatic adenocarcinoma.
- To evaluate pancreatectomy rates, margin status, pathological response, and survival metrics (DFS, DSS, OS) following neoadjuvant therapy.
Main Methods:
- Retrospective review of 121 patients meeting NCCN criteria for borderline resectable pancreatic adenocarcinoma (2006-2013).
- Analysis of pancreatectomy rates, margin status (R0/R1), pathological response, disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS).
- Statistical analysis using standard methods and Kaplan-Meier survival analysis.
Main Results:
- High neoadjuvant therapy completion rate (93.1%) among 101 patients.
- 54.5% of patients underwent pancreatectomy, with 96.4% achieving microscopically negative margins (R0).
- Pancreatectomy correlated with significantly improved median DSS (43 months) and OS (33 months) compared to non-operative management (DSS/OS: 14 months).
Conclusions:
- The investigated neoadjuvant pathway demonstrates high completion and pancreatectomy rates.
- Significant improvements in disease-specific survival were observed post-pancreatectomy.
- The findings support further investigation into this multimodality treatment approach for borderline resectable pancreatic adenocarcinoma.
